参考文献

［1］United Nations, Population Division. World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP/248. D. o. E. a. S. A [R].[S. l.]: United Nations, Population Division, 2017.

［2］ZHOU X J, RAKHEJA D, YU X, et al. The aging kidney [J]. Kidney Int, 2008, 74 (6): 710-20.

［3］United States Renal Data System. 2014 annual data report: An overview of the epidemiology of kidney disease in the United States [R].[S. l.]: National Institutes of Health, 2014.

［4］KOOMAN J P, USVYAT L, THIJSSEN S, et al. Out of control: accelerated aging in uremia [J]. Nephrol Dial Transplant, 2013, 28 (1): 48-54.

［5］STENVINKEL P, LARSSON T E. Chronic kidney disease: a clinical model of premature aging [J]. Am J Kidney Dis, 2013, 62 (2): 339-351.

［6］CHOU Y H, YEN C J, LAI T S. Old age is a positive modifier of renal outcome in Taiwanese patients with stages 3-5 chronic kidney disease [J]. Aging Clin Exp Res, 2019, 31 (11): 1651-1659.

［7］LARSEN C P, BEGGS M L, SAEED M, et al. Histopathologic findings associated with APOL1 risk variants in chronic kidney disease [J]. Mod Pathol, 2015, 28 (1):95-102.

［8］WANNER N, HARTLEBEN B, HERBACH N, et al. Unraveling the role of podocyte turnover in glomerular aging and injury [J]. J Am Soc Nephrol, 2014, 25 (4):707-716.

［9］PERALTA C A, LEE A, ODDEN M C, et al. Association between chronic kidney disease detected using creatinine and cystatin C and death and cardiovascular events in elderly Mexican Americans: the Sacramento Area Latino Study on Aging [J]. J Am Geriatr Soc, 2013, 61 (1):90-95.

［10］TANGRI N, GRAMS M E, LEVEY A S, et al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis [J]. JAMA, 2016, 315 (2): 164-174.

［11］HU M C, SHIIZAKI K, KURO-O M, et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism [J]. Annu Rev Physiol, 2013, 75: 503-533.

［12］WANG S, QIN L, DENG B Q, et al. Elevated cardiac markers in chronic kidney disease as a consequence of hyperphosphatemia-induced cardiac myocyte injury [J]. Med Sci Monit, 2014, 20: 2043-2053.

［13］HU M C, KURO-O M, MOE O W. Alpha Klotho and vascular calcification: an evolving paradigm [J]. Curr Opin Nephrol Hypertens, 2014, 23 (4): 331-339.

［14］BRANDENBURG V M, COZZOLINO M, MAZZAFERRO S. Calcific uremic arteriolopathy: a call for action [J]. Semin Nephrol, 2014, 34 (6): 641-647.

［15］MAFRA D, LOBO J C, BARROS AF, et al. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease [J]. Future Microbiol, 2014, 9 (3): 399-410.

［16］SILVER J, NAVEH-MANY T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease [J]. Nat Rev Nephrol, 2013, 9 (11): 641-649.

［17］LIN C L, WANG S E, HSU C H, et al. Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington′s disease via suppressing oxidative stress, inflammation, and apoptosis [J]. Clin Interv Aging, 2015, 10: 1173-1187.

［18］BARKER S L, PASTOR J, CARRANZA D, et al. The demonstration of alphaKlotho deficiency in human chronic kidney disease with a novel synthetic antibody [J]. Nephrol Dial Transplant, 2015, 30 (2):223-233.

［19］HUMPHREYS B D. Mechanisms of Renal Fibrosis [J]. Annu Rev Physiol, 2018, 80: 309-326.